TY - JOUR
T1 - Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer
AU - Santimaria, Monica
AU - Moscatelli, Giovanni
AU - Viale, Giuseppe L.
AU - Giovannoni, Leonardo
AU - Neri, Giovanni
AU - Viti, Francesca
AU - Leprini, Alessandra
AU - Borsi, Laura
AU - Castellani, Patrizia
AU - Zardi, Luciano
AU - Neri, Dario
AU - Riva, Pietro
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.
AB - Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.
UR - http://www.scopus.com/inward/record.url?scp=0037314650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037314650&partnerID=8YFLogxK
M3 - Article
C2 - 12576420
AN - SCOPUS:0037314650
SN - 1078-0432
VL - 9
SP - 571
EP - 579
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 2
ER -